Please assess the completion status of the following clinical trial:

Trial Title: Assessment of the Transfer of Using Levonorgestrel Intrauterine System (LNG IUS) as a Contraceptive to Using it as Part of Hormone Replacement Therapy (HRT).

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Women with intact uterus, regular menstrual cycles and no previous or current climacteric symptoms.~Exclusion Criteria:~* Pregnancy or lactation.~* Previous pelvic infections.~* Abnormal bleeding.~* Abnormal uterine cavity.~* Uterine polyps.~* Genital cancer.~* Liver diseases.~* Alcoholism or drug abuse.

- Gender: FEMALE
- Minimum Age: 46 Years
- Maximum Age: 51 Years
- Healthy Volunteers: f

Study Arms:
- LNG IUS (Type: EXPERIMENTAL): Levonorgestrel Intrauterine System (LNG IUS) (initial in vitro release 20 µg/24h) intrauterine for minimum of 9 months and maximum of 60 months - 2 phases: a) Contraception Phase b) Hormone-Replacement Therapy (HRT) Phase. For outcome measures (vaginal bleeding variables), five 90-day Reference Periods were defined, which were used for comparison during statistical analysis: Reference Period -1 in Contraception Phase; Reference Periods 1-4 in HRT Phase. 90-day reference periods for analyzing vaginal bleeding data are defined by World Health Organization (WHO) guideline. Reference Period -1 is the last 90-day reference period that the subject had before starting the HRT. Reference Period 1 covers the first 90-days of the HRT phase, Reference Period 2 covers days 91 to 180, Reference Period 3 days 181 to 270, and Reference Period 4 days 271 to 360 of the HRT phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).